|
1
|
Rinella ME, Lazarus JV, Ratziu V, Francque
SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab
JP, et al: A multisociety Delphi consensus statement on new fatty
liver disease nomenclature. J Hepatol. 79:1542–1556.
2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Apostolo D, Ferreira LL, Vincenzi F,
Vercellino N, Minisini R, Latini F, Ferrari B, Burlone M, Pirisi M
and Bellan M: From MASH to HCC: the role of Gas6/TAM receptors.
Front Immunol. 15(1332818)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Phoolchund AGS and Khakoo SI: MASLD and
the Development of HCC: Pathogenesis and Therapeutic Challenges.
Cancers (Basel). 16(259)2024.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Meroni M, Chiappori F, Paolini E, Longo M,
De Caro E, Mosca E, Chiodi A, Merelli I, Badiali S, Maggioni M, et
al: A novel gene signature to diagnose MASLD in metabolically
unhealthy obese individuals. Biochem Pharmacol.
218(115925)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Younossi ZM, Golabi P, Paik JM, Henry A,
Van Dongen C and Henry L: The global epidemiology of nonalcoholic
fatty liver disease (NAFLD) and nonalcoholic steatohepatitis
(NASH): A systematic review. Hepatology. 77:1335–1347.
2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mellemkjær A, Kjær MB, Haldrup D, Grønbæk
H and Thomsen KL: Management of cardiovascular risk in patients
with metabolic dysfunction-associated steatotic liver disease. Eur
J Intern Med. 122:28–34. 2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Younossi ZM: Non-alcoholic fatty liver
disease-A global public health perspective. J Hepatol. 70:531–544.
2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Michalczuk MT, Longo L, Keingeski MB,
Basso BS, Guerreiro GTS, Ferrari JT, Vargas JE, Oliveira CP,
Uribe-Cruz C, Cerski CTS, et al: Rifaximin on epigenetics and
autophagy in animal model of hepatocellular carcinoma secondary to
metabolic-dysfunction associated steatotic liver disease. World J
Hepatol. 16:75–90. 2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Maliakkal BJ: Pathogenesis of
non-alcoholic fatty liver disease and implications on
cardiovascular outcomes in liver transplantation. Transl
Gastroenterol Hepatol. 5(36)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kim H, Lee DS, An TH, Park HJ, Kim WK, Bae
KH and Oh KJ: Metabolic spectrum of liver failure in type 2
diabetes and obesity: From NAFLD to NASH to HCC. Int J Mol Sci.
22(4495)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Rizzo A, Mollica V, Tateo V, Tassinari E,
Marchetti A, Rosellini M, De Luca R, Santoni M and Massari F:
Hypertransaminasemia in cancer patients receiving immunotherapy and
immune-based combinations: The MOUSEION-05 study. Cancer Immunol
Immunother. 72:1381–194. 2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Rizzo A, Ricci AD and Brandi G: Systemic
adjuvant treatment in hepatocellular carcinoma: Tempted to do
something rather than nothing. Future Oncol. 16:2587–2589.
2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Guven DC, Sahin TK, Erul E, Rizzo A, Ricci
AD, Aksoy S and Yalcin S: The association between albumin levels
and survival in patients treated with immune checkpoint inhibitors:
A systematic review and meta-analysis. Front Mol Biosci.
9(1039121)2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Rizzo A, Ricci AD and Brandi G:
Trans-Arterial chemoembolization plus systemic treatments for
hepatocellular carcinoma: An Update. J Pers Med.
12(1788)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang S and Friedman SL: Found in
translation-Fibrosis in metabolic dysfunction-associated
steatohepatitis (MASH). Sci Transl Med. 15(eadi0759)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Cobbold JFL, Atkinson S, Marchesi JR,
Smith A, Wai SN, Stove J, Shojaee-Moradie F, Jackson N, Umpleby AM,
Fitzpatrick J, et al: Rifaximin in non-alcoholic steatohepatitis:
An open-label pilot study. Hepatol Res. 48:69–77. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Leone P, Mincheva G, Balzano T,
Malaguarnera M, Felipo V and Llansola M: Rifaximin Improves spatial
learning and memory impairment in rats with liver Damage-Associated
neuroinflammation. Biomedicines. 10(1263)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gangarapu V, Ince AT, Baysal B, Kayar Y,
Kılıç U, Gök Ö, Uysal Ö and Şenturk H: Efficacy of rifaximin on
circulating endotoxins and cytokines in patients with nonalcoholic
fatty liver disease. Eur J Gastroenterol Hepatol. 27:840–845.
2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Fang J, Celton-Morizur S and Desdouets C:
NAFLD-Related HCC: Focus on the latest relevant preclinical models.
Cancers (Basel). 15(3723)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
de Lima VM, Oliveira CP, Alves VA, Chammas
MC, Oliveira EP, Stefano JT, de Mello ES, Cerri GG, Carrilho FJ and
Caldwell SH: A rodent model of NASH with cirrhosis, oval cell
proliferation and hepatocellular carcinoma. J Hepatol.
49:1055–1061. 2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
de Moura RF, Ribeiro C, de Oliveira JA,
Stevanato E and de Mello MA: Metabolic syndrome signs in Wistar
rats submitted to different high-fructose ingestion protocols. Br J
Nutr. 101:1178–1184. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Longo L, Tonin Ferrari J, Rampelotto PH,
Hirata Dellavia G, Pasqualotto A, P Oliveira C, Thadeu Schmidt
Cerski C, Reverbel da Silveira T, Uribe-Cruz C and Álvares-da-Silva
MR: Gut dysbiosis and increased intestinal permeability Drive
microRNAs, NLRP-3 inflammasome and liver fibrosis in a nutritional
model of Non-Alcoholic steatohepatitis in adult male sprague dawley
rats. Clin Exp Gastroenterol. 13:351–368. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Dapito DH, Mencin A, Gwak GY, Pradere JP,
Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A,
Bataller R, et al: Promotion of hepatocellular carcinoma by the
intestinal microbiota and TLR4. Cancer Cell. 21:504–516.
2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sujatha R and Kavitha S: Atherogenic
indices in stroke patients: A retrospective study. Iran J Neurol.
16:78–82. 2017.PubMed/NCBI
|
|
25
|
Gómez-Lechón MJ, Donato MT,
Martínez-Romero A, Jiménez N, Castell JV and O'Connor JE: A human
hepatocellular in vitro model to investigate steatosis. Chem Biol
Interact. 165:106–116. 2007.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Liang W, Menke AL, Driessen A, Koek GH,
Lindeman JH, Stoop R, Havekes LM, Kleemann R and van den Hoek AM:
Establishment of a general NAFLD scoring system for rodent models
and comparison to human liver pathology. PLoS One.
9(e115922)2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Edmondson HA and Steiner PE: Primary
carcinoma of the liver: A study of 100 cases among 48,900
necropsies. Cancer. 7:462–503. 1954.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ferrari JT, Guerreiro GTS, Longo L,
Silveira TR, Cerski CTS, Tozawa E, Oliveira CP, Álvares-da-Silva MR
and Uribe-Cruz C: Potential beneficial effect of rifaximin in the
prevention of hepatocellular carcinoma through the modulation of
the microbiota in an experimental model of non-alcoholic fatty
liver disease. Acta Gastroenterol Latinoam. 53:265–282. 2023.
|
|
31
|
Guerreiro GTS, Longo L, Fonseca MA, de
Souza VEG and Álvares-da-Silva MR: Does the risk of cardiovascular
events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int,
2021.
|
|
32
|
Zacharias HD, Kamel F, Tan J, Kimer N,
Gluud LL and Morgan MY: Rifaximin for prevention and treatment of
hepatic encephalopathy in people with cirrhosis. Cochrane Database
Syst Rev. 7(CD011585)2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Patel VC, Lee S, McPhail MJW, Da Silva K,
Guilly S, Zamalloa A, Witherden E, Støy S, Manakkat Vijay GK, Pons
N, et al: Rifaximin-α reduces gut-derived inflammation and mucin
degradation in cirrhosis and encephalopathy: RIFSYS randomised
controlled trial. J Hepatol. 76:332–342. 2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Pomej K, Balcar L, Scheiner B, Semmler G,
Meischl T, Mandorfer M, Reiberger T, Müller C, Trauner M, Pinter M,
et al: Antibiotic therapy is associated with worse outcome in
patients with hepatocellular carcinoma treated with sorafenib. J
Hepatocell Carcinoma. 8:1485–1493. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Flessa CM, Nasiri-Ansari N, Kyrou I, Leca
BM, Lianou M, Chatzigeorgiou A, Kaltsas G, Kassi E and Randeva HS:
Genetic and Diet-Induced Animal Models for Non-Alcoholic fatty
liver disease (NAFLD) research. Int J Mol Sci.
23(15791)2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Denk H, Abuja PM and Zatloukal K: Animal
models of NAFLD from the pathologist's point of view. Biochim
Biophys Acta Mol Basis Dis. 1865:929–942. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Longo L, Rampelotto PH, Filippi-Chiela E,
de Souza VEG, Salvati F, Cerski CT, da Silveira TR, Oliveira CP,
Uribe-Cruz C and Álvares-da-Silva MR: Gut dysbiosis and systemic
inflammation promote cardiomyocyte abnormalities in an experimental
model of steatohepatitis. World J Hepatol. 13:2052–2070.
2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hadizadeh F, Faghihimani E and Adibi P:
Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J
Gastrointest Pathophysiol. 8:11–26. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Sanyal D, Mukherjee P, Raychaudhuri M,
Ghosh S, Mukherjee S and Chowdhury S: Profile of liver enzymes in
non-alcoholic fatty liver disease in patients with impaired glucose
tolerance and newly detected untreated type 2 diabetes. Indian J
Endocrinol Metab. 19:597–601. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Uehara T, Pogribny IP and Rusyn I: The DEN
and CCl4-Induced mouse model of fibrosis and
inflammation-associated hepatocellular carcinoma. Curr Protoc
Pharmacol. 66(14.30.1-10)2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Oseini AM, Cole BK, Issa D, Feaver RE and
Sanyal AJ: Translating scientific discovery: The need for
preclinical models of nonalcoholic steatohepatitis. Hepatol Int.
12:6–16. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Lee S and Saffo S: Evolution of care in
cirrhosis: Preventing hepatic decompensation through
pharmacotherapy. World J Gastroenterol. 29:61–74. 2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Jian J, Nie MT, Xiang B, Qian H, Yin C,
Zhang X, Zhang M, Zhu X and Xie WF: Rifaximin ameliorates
non-alcoholic steatohepatitis in mice through regulating gut
microbiome-related bile acids. Front Pharmacol.
13(841132)2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Fujinaga Y, Kawaratani H, Kaya D, Tsuji Y,
Ozutsumi T, Furukawa M, Kitagawa K, Sato S, Nishimura N, Sawada Y,
et al: Effective combination therapy of Angiotensin-II receptor
blocker and rifaximin for hepatic fibrosis in rat model of
nonalcoholic steatohepatitis. Int J Mol Sci.
21(5589)2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Cheng J, Krausz KW, Tanaka N and Gonzalez
FJ: Chronic exposure to rifaximin causes hepatic steatosis in
pregnane X receptor-humanized mice. Toxicol Sci. 129:456–468.
2012.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Abdel-Razik A, Mousa N, Shabana W, Refaey
M, Elzehery R, Elhelaly R, Zalata K, Abdelsalam M, Eldeeb AA, Awad
M, et al: Rifaximin in nonalcoholic fatty liver disease: hit
multiple targets with a single shot. Eur J Gastroenterol Hepatol.
30:1237–1246. 2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Zhang L, Xie Z, Yu H, Du H, Wang X, Cai J,
Qiu Y, Chen R, Jiang X, Liu Z, et al: TLR2 inhibition ameliorates
the amplification effect of LPS on lipid accumulation and
lipotoxicity in hepatic cells. Ann Transl Med.
9(1429)2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ranoa DRE, Kelley SL and Tapping RI: Human
lipopolysaccharide-binding protein (LBP) and CD14 independently
deliver triacylated lipoproteins to Toll-like receptor 1 (TLR1) and
TLR2 and enhance formation of the ternary signaling complex. J Biol
Chem. 288:9729–9741. 2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Asgharpour A, Cazanave SC, Pacana T,
Seneshaw M, Vincent R, Banini BA, Kumar DP, Daita K, Min HK,
Mirshahi F, et al: A diet-induced animal model of non-alcoholic
fatty liver disease and hepatocellular cancer. J Hepatol.
65:579–588. 2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Lau JK, Zhang X and Yu J: Animal models of
non-alcoholic fatty liver disease: Current perspectives and recent
advances. J Pathol. 241:36–44. 2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Febbraio MA, Reibe S, Shalapour S, Ooi GJ,
Watt MJ and Karin M: Preclinical models for studying NASH-Driven
HCC: How useful are they? Cell Metab. 29:18–26. 2019.PubMed/NCBI View Article : Google Scholar
|
